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Dacomitinib, a pan-inhibitor
of ErbB receptors, suppresses
growth and invasive capacity of
chemoresistant ovarian carcinoma
cells
Majid Momeny1, Ghazaleh Zarrinrad1, Farima Moghaddaskho1, Arash Poursheikhani2,
Ghazaleh Sankanian1, Azam Zaghal1, Shahab Mirshahvaladi3, Fatemeh Esmaeili2, Haniyeh
Eyvani1, Farinaz Barghi1, Zahra Sabourinejad1, Zivar Alishahi2, Hassan Yousefi2, Reza
Ghasemi4, Leila Dardaei5, Davood Bashash6, Bahram Chahardouli 1, Ahmad R. Dehpour7,8,
Javad Tavakkoly-Bazzaz2, Kamran Alimoghaddam1, Ardeshir Ghavamzadeh1 &
Seyed H. Ghaffari1
Epithelial ovarian cancer (EOC) is the most lethal gynaecological malignancy worldwide. Development
of chemoresistance and peritoneal dissemination of EOC cells are the major reasons for low survival
rate. Targeting signal transduction pathways which promote therapy resistance and metastatic
dissemination is the key to successful treatment. Members of the ErbB family of receptors are overexpressed in EOC and play key roles in chemoresistance and invasiveness. Despite this, single-targeted
ErbB inhibitors have demonstrated limited activity in chemoresistant EOC. In this report, we show
that dacomitinib, a pan-ErbB receptor inhibitor, diminished growth, clonogenic potential, anoikis
resistance and induced apoptotic cell death in therapy-resistant EOC cells. Dacominitib inhibited
PLK1-FOXM1 signalling pathway and its down-stream targets Aurora kinase B and survivin. Moreover,
dacomitinib attenuated migration and invasion of the EOC cells and reduced expression of epithelial-tomesenchymal transition (EMT) markers ZEB1, ZEB2 and CDH2 (which encodes N-cadherin). Conversely,
the anti-tumour activity of single-targeted ErbB agents including cetuximab (a ligand-blocking
anti-EGFR mAb), transtuzumab (anti-HER2 mAb), H3.105.5 (anti-HER3 mAb) and erlotinib (EGFR
small-molecule tyrosine kinase inhibitor) were marginal. Our results provide a rationale for further
investigation on the therapeutic potential of dacomitinib in treatment of the chemoresistant EOC.
Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer-related death among women worldwide and
accounts for the highest mortality rate of all gynaecological malignancies. Each year, over 22000 women are
diagnosed with EOC in the United States an estimated 14000 patients die from this disease1. Late-stage diagnosis,
peritoneal metastasis and development of chemoresistance restrain improvements in overall survival rate. Despite
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Chemosensitivity (IC50)a
Cell Lines

Cisplatin
(μg/mL)

Carboplatin
(μg/mL)

Paclitaxel
(μg/mL)

Doxorubicin
(ng/mL)

Vincristine
(ng/mL)

Gemcitabine
(ng/mL)

Erlotinib
(μM)

Cetuximab
(μg/mL)

OVCAR3

1.025

797.2

1.894

432.2

>1000

153.9

64.13

>100

SKOV3

5.799

71.32

5.355

696.1

>1000

24.14

113.6

>100

A2780CP

1.145

50.61

1.358

598.9

37.01

26.56

10.30

>100

A2780S

0.8634

4.594

0.2092

4.063

32.25

15.87

5.244

82.31

Caov4

0.3427

2.661

0.1155

5.102

3.430

4.560

2.635

43.89

Table 1. Chemosensitivity of a panel of EOC cell lines to certain chemotherapeutics and targeted therapies.
Data represent the average of IC50 values and were collected from three independent experiments, each
performed in triplicate. IC50 is the concentration of drug that caused a 50% reduction in proliferation compared
to the vehicle-treated cells.
debulking surgery and aggressive platinum/taxane-based chemotherapy regimens, the majority of patients
relapse after achieving a complete clinical response2, 3. Inherent and acquired resistance to chemotherapeutics
are responsible for treatment failure in EOC4. Patients with the recurrent disease are treated with gemcitabine
and bevacizumab (anti-VEGFA mAb) but clinical trials report that the median overall survival is still dismal5, 6.
Therefore, there is a pressing need to establish more effective therapies against chemoresistant EOC.
The ErbB or epidermal growth factor (EGF) family of receptor tyrosine kinases consists of four closely related
members including EGFR, HER2, HER3 and HER47. This family plays key roles in tumour growth, metastasis and therapy resistance through activation of down-stream pathways such as Ras/MAPK and PI3K/AKT8, 9.
Evidence indicates that the ErbB family members are overexpressed in EOC which correlates with poor survival10.
EGFR is overexpressed in 30–98% of EOC in all histologic subtypes11, 12. Enhanced expression of EGFR and its
ligands correlate with advanced-stage disease, lack of therapeutic response and decreased recurrence-free survival13–15. HER2 gene amplification and over-expression are found in different subtypes of EOC and associate with
a higher recurrence frequency16, 17. Moreover, HER3 is up-regulated in EOC clinical samples which correlates
with a worse prognosis18, 19.
The ErbB family is thought to drive malignant progression in EOC20, 21. EGFR and HER2 promote growth
and chemoresistance22, 23. Moreover, HER3 and its ligand heregulin (HRG) play a central role in hematogenous
dissemination of EOC cells to the omentum. HER3 is highly expressed in omental metastases in EOC patients
and its knockdown impairs this organotropism in vivo24. Altogether, these studies highlight the importance of
the ErbB network in promoting growth, chemoresistance and metastatic progression in EOC and suggest that
therapeutically disabling this family may hinder growth, survival and motility of EOC cells.
Despite the importance of EGFR in malignant progression in EOC, clinical trials with single-targeted agents
such as cetuximab (anti-EGFR mAb), gefitinib and erlotinib (EGFR small molecule inhibitors) have demonstrated
limited activity25–27. Trials of EGFR-directed therapies in combination with chemotherapeutics or other targeted
therapies such as bevacizumab have also shown limited clinical benefit28–30. Furthermore, HER2-targeted therapies including trastuzumab and pertuzumab have proven to be of no benefit in EOC patients31, 32. Refinement
of the ErbB-targeted therapeutics is therefore warranted to address resistance and maximize potential benefit in
EOC patients.
Dacomitinib (Pfizer) is an irreversible second-generation pan-ErbB inhibitor33. A phase I study in patients
with advanced solid tumours has demonstrated well-tolerated doses with significant antitumor activity34.
Dacomitinib has shown promising clinical activity in advanced non-small cell lung cancer patients who progressed on platinum therapy and were previously treated with erlotinib35, 36. In vitro studies have reported significant anti-tumour activity of dacomitinib in gefitinib-resistant lung cancer as well as breast cancer cell lines
which are resistant to trastuzumab and lapatinib (a dual HER2 and EGFR inhibitor)37, 38. In the present study, we
examined the mechanistic activity of dacomitinib in chemoresistant EOC cells.

Results

Chemosensitivity of the EOC cell lines. The chemoresponsiveness of a panel of EOC cell lines to certain
chemotherapeutics and targeted therapies were determined by MTT assay and are summarized in Table 1. These
data show that OVCAR3, SKOV3 and A2780CP cells exhibit resistance to carboplatin, doxorubicin and cetuximab, as compared to A2780S and Caov4 cells (Table 1; Supplementary Fig. 1).
Expression of the ErbB family in the EOC cells. The expression of the ErbB family in chemoresistant ver-

sus sensitive EOC cells is not yet examined. To determine potential association between chemoresponsiveness and
expression of the ErbB family, their relative expression was investigated by qRT-PCR. Using Tukey’s post hoc analysis, we found no difference in the expression of the ErbB family between the two groups of the EOC cells (Fig. 1A,B).

The ErbB family contributes to cisplatin resistance.

In an attempt to examine possible correlation
between the mRNA levels of the ErbB family and chemoresponsiveness, we found that higher expression of
HRG1-α and HRG1-β are significantly associated with resistance to cisplatin by Pearson’s correlation (Fig. 2A).
The correlation coefficient (r) between the expression of HRG1-α and HRG1-β and cisplatin IC50 values is 0.9058
(P = 0.034) and 0.8997 (P = 0.037), respectively. In addition, our data demonstrated positive correlation between
cisplatin resistance and higher expression of EGFR and HER2 (Fig. 2A). We found no significant association

Scientific Reports | 7: 4204 | DOI:10.1038/s41598-017-04147-0

2

www.nature.com/scientificreports/

Figure 1. Expression of the ErbB family in the EOC cells. (A,B) The mRNA levels of the ErbB family in the
EOC cell lines were determined by qRT-PCR. The data were evaluated in triplicate and collected from three
independent experiments. Gene expression levels were normalised to B2M in each cell line. Data were analysed
by one-way ANOVA followed by Tukey’s post hoc test and are shown as mean ± SD. Statistically significant
values of *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 were determined.
between the ErbB family expression and resistance to carboplatin, paclitaxel, doxorubicin, gemcitabine and erlotinib (Supplementary Fig. 2).
Expression of both HRG1-α and HRG1-β has been observed in 30–83% of EOC cell lines and tumour samples39. After binding to HRG, HER3 heterodimerises with the other ErbB receptors, which activates down-stream
pro-survival pathways40. HRG1-β binds to HER3 with more affinity and induces greater activation of the ErbB
receptors than HRG1-α41, 42. We therefore explored the effects of exogenous HRGβ-1 on proliferative response
of the chemosensitive Caov4 cells to cisplatin. The resulting data show that pre-treatment with HRGβ-1 (10 ng/
mL) decreased cisplatin-induced cytotoxicity, a process abrogated when the cells were pre-treated with dacomitinib but not single-targeted ErbB inhibitors including cetuximab, erlotinib, trastuzumab and H3.105.5 (a
ligand-blocking anti-HER3 antibody) (Fig. 2C).
We next compared the effects of the ErbB inhibitors on potentiation of the anti-tumour effects of cisplatin
in the chemoresistant EOC cells. Combination of dacomitinib with cisplatin had a synergistic effect on growth
inhibition. In comparison, erlotinib-cisplatin therapy was antagonistic (Fig. 2D,E; Supplementary Tables 1, 2).
Altogether, these findings suggest that the ErbB family might contribute to cisplatin resistance and a pan-ErbB
inhibition strategy is required to augment cisplatin efficacy in the chemoresistant EOC cells.

Dacomitinib inhibits cell viability and induces apoptosis. MTT assay was performed to estimate
anti-proliferative effects of the anti-ErbB agents on the chemoresistant EOC cells. Treatment with dacomitinib
inhibited cell growth (Fig. 3A,B). Clonogenic capacity represents the renewal potential and a long-term response
of cells after treatment. The results of a colony formation assay demonstrate that both trastuzumab and dacomitinib reduced clonogenic survival (Fig. 3C). In immortalized cells, detachment from the extracellular matrix
induces anoikis, a special type of apoptosis43. Acquisition of resistance to anoikis is a prerequisite for EOC cells to
survive in ascites before forming metastatic foci44. Our data show that dacomitinib diminished anoikis resistance
(Fig. 3D). Moreover, dacomitinib but not the single-targeted agents induced apoptotic cell death, as demonstrated
by Annexin V staining (Fig. 3E). These data suggest that dacomitinib had stronger anti-proliferative efficacy compared to the single-targeted ErbB inhibitors (Fig. 3A–E).
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Figure 2. The ErbB family contributes to cisplatin resistance. (A) Correlation of expression of HRG1-α,
HRG1-β, EGFR and HER2 with resistance to cisplatin. EOC cell lines with higher expression of HRG1-α,
HRG1-β, EGFR and HER2 showed significantly higher cisplatin IC50 values. The correlation coefficient (r)
between the expression of EGFR and HER2 and cisplatin concentrations was 0.917 (P = 0.0281) and 0.890
(P = 0.0341), respectively. (B) Dacomitinib inhibits ErbB activation. The effect of dacomitinib (5 μM) on ErbB
activation was determined by Western blot analysis. Protein lysates were subjected to Western blotting and
probed with the indicated antibodies. β-actin was used as the loading control. The blots are representative of
three independent experiments with similar results. (C) The effects of the ErbB inhibitors on HRGβ-1-induced
proliferation in cisplatin-treated Caov4 cells were shown by MTT assay. The cells were pre-treated with the
anti-ErbB agents for 4 h, followed by treatment with HRGβ-1 for 48 h. (D) The effects of the ErbB inhibitorscisplatin therapy on cell proliferation were investigated by MTT assay after 48 h of treatment and the data are
shown by IC50 shift analysis. The concentrations of cisplatin were 0.1, 0.5, 1, 2.5, 5 and 10 μg/mL. (E) Normalised
isobolograms of combination of erlotinib (5 μM) and dacomitinib (5 μM) with cisplatin. The data were analysed
using the CalcuSyn software. The connecting line represents additivity. Data points located below the line
indicate a synergistic drug-drug interaction and data points above the line indicate an antagonistic interaction.
The numbers under the isobolograms indicate the concentrations of the drugs in combination. Data shown
represent the mean ± SD from three independent experiments, each performed in triplicate. Statistically
significant values of *p < 0.05 and **p < 0.01 were determined compared with the control.

Dacomitinib inhibits PLK1-FOXM1 signalling. Polo-like kinase 1 (PLK1) is a serine/threonine protein

kinase which plays a central role in mitotic progression and its elevated expression in EOC correlates with histological grade45. PLK1 induces forkhead box protein M1 (FOXM1), a member of FOX family of transcription
factors that regulates expression of a wide range of genes such as PLK1, survivin (encoded by BIRC5), cyclin B1
(encoded by CCNB1) and Aurora kinase B (encoded by AURKB)46, 47. The FOXM1-target genes participate in
different cellular functions including cell growth, metastatic dissemination and therapy resistance48, 49.
PLK1 has been shown to mediate resistance to chemotherapeutics including cisplatin50. To determine if the
ErbB family activates PLK1 in the EOC cells, the cells were serum-starved for 24 h and then treated with HRGβ-1
(10 ng/mL) for 30 min. Immunoblotting analysis showed that HRGβ-1 stimulation resulted in activation of PLK1
(Fig. 4A). This is in consistency with previous reports that the ErbB receptors activate the PLK1-FOXM1 axis51, 52.
We next sought if dacomitinib-induced sensitisation to cisplatin is through inhibition of PLK1 pathway. To
achieve this, the cells were treated with cisplatin in combination with BI 2536, a highly selective PLK1 inhibitor. Our findings demonstrate that BI 2536 had synergistic activity with cisplatin on inhibition of cell growth
(Fig. 4B,C; Table 2), suggesting that PLK1 blockade enhances sensitivity to cisplatin.
We therefore evaluated the effects of dacomitinib on PLK1-FOXM1 signalling. Our data show that dacomitinib, but not the single-targeted agents, inhibited p-PLK1 (Fig. 4D). Furthermore, dacomitinib reduced the
mRNA and protein levels of FOXM1, survivin and Aurora kinase B. Conversely, the inhibitory effects of the
single-targeted agents were marginal (Fig. 4D,E). Altogether, these data suggest that PLK1 blockade is a mechanism for dacomitinib-induced sensitisation to cisplatin and that a comprehensive ErbB inhibition strategy is
required for blockade of PLK1-FOXM1 pathway and its down-stream targets.
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Figure 3. Dacomitinib inhibits cell growth and induces apoptosis. (A) The effects of the ErbB inhibitors on cell
proliferation were estimated by MTT assay after 48 h of treatment. (B) The effects of the anti-ErbB agents on cell
viability were demonstrated by crystal violet staining. The cells were treated with the ErbB inhibitors for 48 h,
then stained with crystal violet and imaged by an inverted microscope (images acquired at 10x magnification).
(C) Clonogenic assay was conducted to evaluate the effects of the ErbB inhibitors on clonal proliferation. (D)
Anoikis resistance assay was performed with cell culture on poly-HEMA–coated culture dishes for 48 h and
the proportion of viable cells was measured by MTT assay. (E) The effects of the anti-ErbB agents on induction
of apoptosis were determined by annexin V staining. Annexin V-positive cells are considered early apoptotic,
whereas PI uptake indicates necrosis. Cells positive for both stains are considered late apoptotic. The graphs are
representative of three independent experiments with similar outcomes. Data shown represent the mean ± SD
from three independent experiments, each performed in triplicate. Statistically significant values of *p < 0.05,
**p < 0.01, and ***p < 0.001 were determined compared with the control.

Dacomitinib reduces migration and invasion. Ovarian cancer metastasis includes tumour cells detachment from the primary site followed by their spread to the peritoneum and omentum53. The degree of peritoneal
dissemination associates with poor prognosis54. Detachment of EOC cells from the primary site and their local
invasion is driven by an epithelial-to-mesenchymal transition (EMT)55. EMT is triggered by down-regulation of
cell adhesion molecules by transcriptional repressors ZEB1, ZEB2 and Snail56. It is thought that EMT contributes
to loosening of intercellular adhesions and shedding of EOC cells into ascites57. We next determined the effects
of dacomitinib on expression of the EMT markers ZEB1, ZEB2 and CDH2 (which encodes N-cadherin). The
resulting data indicate that dacomitinib had stronger inhibitory effects on the expression of the EMT markers, as
compared to the single-targeted agents (Fig. 5A). Moreover, these data show that dacomitinib hindered migration
and invasion of the EOC cells through matrigel (Fig. 5B).

Discussion

There is evidence that the ErbB signalling network contributes to chemoresistance in EOC. EGFR drives resistance to cisplatin through induction of the anti-apoptotic protein Bcl-258. HER2 promotes resistance to taxane
chemotherapies and its depletion enhances chemosensitivity59. Moreover, activation of HER3 has been demonstrated to drive chemoresistance in EOC cells via activation of AKT pathway60. These findings suggest that the
ErbB family is a potential therapeutic target in the chemoresistant EOC and its blockade might inhibit tumour
growth and induce chemosensitisation61.
During ovarian carcinoma metastasis, epithelial cells lose E-cadherin-mediated cell-cell interactions,
up-regulate N-cadherin and undergo EMT62. Evidence indicates that EMT correlates with a poor prognosis in
EOC63, 64. Moreover, EMT is thought to drive a chemoresistant behaviour65, 66. Induction of EMT promotes peritoneal dissemination and reversing the EMTed phenotype is believed to be a novel strategy to hamper intraperitoneal metastasis67. Targeting signalling pathways contributing to EMT is a potential therapeutic approach in
order to hinder invasiveness of EOC cells68. Both EGFR and HER2 downregulate E-cadherin expression, induce
an EMTed phenotype and increase motility of EOC cells69, 70. The results of the present study suggest that blocking
Scientific Reports | 7: 4204 | DOI:10.1038/s41598-017-04147-0
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Figure 4. Dacomitinib inhibits PLK1-FOXM1 pathway. (A) HRG/HER3 loop activates PLK1. The effects of
HRGβ-1 on PLK1 activation was determined by Western blot analysis. Protein lysates from serum-starved and
HRGβ-1-treated cells were subjected to Western blotting and probed with the indicated antibodies. The blots are
representative of three independent experiments with similar outcomes. (B) PLK1 blockade increases cisplatin
sensitivity. The effects of BI 2536-cisplatin therapy on cell proliferation were investigated by MTT assay and
shown by IC50 shift analysis. The cultures were treated with BI 2536 (20 nM) and cisplatin (0.1, 0.5, 1, 2.5, 5 and
10 μg/mL) for 48 h. (C) Normalised isobolograms of combination of BI 2536 and cisplatin. (D) The effects of
cetuximab (10 μg/mL), trastuzumab (10 μg/mL), H3.105.5 (10 μg/mL), erlotinib (5 μM) and dacomitinib (5 μM)
on PLK1-FOXM1 pathway and its down-stream targets were determined by Western blot analysis. The blots are
representative of three independent experiments with similar outcomes. (E) The effects of the anti-ErbB agents
on the expression of PLK1-FOXM1 targets genes were determined by qRT-PCR analysis. Data shown represent
the mean ± SD from three independent experiments, each performed in triplicate. Statistically significant values
of *p < 0.05, **p < 0.01, and ***p < 0.001 were determined compared with the control. SFM, serum-free media;
CCNB1, cyclin B1; CDC25C, cell division cycle 25C; CDK1, cyclin-dependent kinase 1; FOXM1, Forkhead box
M1; AURKB, Aurora kinase B; BIRC5, survivin.

the ErbB receptors by dacomitinib is an effective strategy in order to reduce the expression of the EMT markers
and hamper invasive capability of the chemoresistant EOC cells.
Single-targeted ErbB agents have shown minimum response in chemoresistant ECO patients26, 31, 71.
Compensatory activation of the other ErbB receptors sustains the activation of common downstream pro-survival
pathways72. Targeting all the ErbB receptors is therefore a more effective treatment strategy, especially when
resistance to a single-targeted ErbB agent has occurred73. For instance, breast cancer patients who experienced
tumour progression after treatment with trastuzumab have demonstrated response to the dual EGFR and HER2
inhibitor lapatinib74. Furthermore, cetuximab-resistant colorectal and head and neck squamous cell carcinoma
cells are sensitive to pan-ErbB inhibitors75–77. In consistency, our data show that the inhibitory effects of the
single-targeted ErbB inhibitors on viability and invasiveness of the chemoresistant EOC cells were marginal.
Conversely, dacomitinib exerted pronounced anti-tumour activity, suggesting that it may have potential for treatment of the EOC patients who ultimately have developed resistance after initial response.
Taken together, the results of the present study provide new insight into the mechanistic activity of dacomitinib
through inhibition of the PLK1-FOXM1 axis (Fig. 6). These findings also indicate that dacomitinib-mediated
Scientific Reports | 7: 4204 | DOI:10.1038/s41598-017-04147-0
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Concentrations
BI 2536 (nM)

DRI
Cisplatin (μg/mL)

fa

CI

BI 2536

Cisplatin

20

0.1

0.23

0.724

2.442

3.181

20

0.5

0.42

0.658

10.405

1.780

20

1

0.51

0.832

17.559

1.290

20

2.5

0.64

1.083

41.129

0.944

20

5

0.75

1.136

100.142

0.888

20

10

0.90

0.693

529.397

1.448

20

0.1

0.45

0.049

424.093

21.290

20

0.5

0.46

0.229

624.218

4.393

20

1

0.49

0.402

2972.447

2.491

20

2.5

0.62

0.640

7.8e + 005

1.562

20

5

0.79

0.627

5.39e + 009

1.594

20

10

0.84

0.944

1.83e + 011

1.060

20

0.1

0.55

0.797

1.278

70.538

20

0.5

0.57

0.818

1.327

15.428

20

1

0.59

0.836

1.389

8.592

20

2.5

0.6

0.974

1.426

3.661

20

5

0.66

1.012

1.629

2.511

20

10

0.76

0.863

2.172

2.483

OVCAR3

SKOV3

A2780CP

Table 2. Combination index (CI) and dose reduction index (DRI) of BI 2536 and cisplatin combination in
OVCAR3, SKOV3 and A2780CP cells. DRI represents the order of magnitude of dose reduction that is allowed in
combination for a given degree of effect as compared with the dose of each drug alone. “fa” denotes fraction affected.

Figure 5. Dacomitinib inhibits migration and invasion. (A) The effects of the anti-ErbB agents on expression
of EMT markers were determined by qRT-PCR analysis. (B) The effects of the ErbB inhibitors on cell migration
and invasion. The cells were placed into 8-μm porous culture inserts, treated with the drugs and allowed to
migrate for 48 h. The migrated cells on the lower surface of the inserts were quantified by crystal violet staining.
For invasion assay, the cells were placed into matrigel-coated inserts and allowed to invade through the matrigel
layer for 48 h. Data shown represent the mean ± SD from three independent experiments, each performed in
triplicate. Statistically significant values of *p < 0.05 and **p < 0.01 were determined compared with the control.
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Figure 6. Schematic illustration of the anti-tumour effects of dacomitinib on the EOC cells. Dacomitinib
inhibited cell growth, induced apoptosis and restored cisplatin sensitivity through blockade of the PLK1/
FOXM1 axis and its downstream targets Aurora B and survivin.

blockade of the ErbB receptors provides advantages over single-targeted ErbB inhibitors and thus offer a novel
and promising treatment strategy to address chemoresistance in EOC. Further in vivo investigations are warranted to explore the anti-tumour activity of dacomitinib in therapy-resistant EOC.

Materials and Methods

Antibodies and chemicals. Antibodies were obtained as follows: Aurora B (Abcam); EGFR, HER2, HER3
(clone 2F12) and HER3-neutralising monoclonal antibody (clone H3.105.5) (Millipore); p-EGFR (Tyr1068),
p-HER2 (Tyr1248), p-HER3 (Tyr1289; clone 21D3), p-HER4 (Tyr1284; clone 21A9) and p-PLK1 (Thr210) (Cell
Signalling Technology); HER4 (clone C-7), PLK1 (clone F-8), FOXM1 (clone C-20), survivin (clone FL-142)
and β-actin (Santa Cruz Biotechnology). Dacomitinib and BI 2536 (a specific inhibitor of polo-like kinase 1)
were purchased from Adooq Bioscience (Irvine, CA, USA) and were dissolved in DMSO. The final concentrations of DMSO did not exceed than 0.1% [v/v] in all the treatments. Erlotinib (EGFR small molecule inhibitor)
was obtained from Chemietek (Indianapolis, IN, USA). Cetuximab (a ligand-blocking anti-EGFR mAb), trastuzumab (anti-HER2 mAb), cisplatin and doxorubicin (DNA-damaging drugs), paclitaxel (a taxane inhibitor
of microtubule disassembly), vincristine (a mitosis-blocking agent), carboplatin (an alkylating agent) and gemcitabine (a nucleoside analogue which inhibits DNA synthesis) were purchased from the pharmacy of Shariati
hospital (Tehran, Iran). Poly-hydroxyethylmethacrylate polymer (poly-HEMA) was obtained from Santa Cruz
Biotechnology. Recombinant HRGβ-1 was purchased from Peprotech.
Human ovarian carcinoma cell lines. Human ovarian carcinoma cell lines were obtained from National
Cell Bank of Iran (NCBI, Tehran, Iran). These include A2780CP, A2780S, Caov4, OVCAR3 and SKOV3. All the
cell lines were authenticated by STR profiling and were routinely checked for mycoplasma infection. Cell cultures
were maintained at 37 °C in 5% CO2 in a humidified incubator and cultured according to NCBI recommendations.
Chemosensitivity assay.

The EOC cells were seeded at 2 × 103 per well in 96-well plates and treated with
the chemotherapeutics for 48 h. Cell viability was determined by MTT assay. Vehicle-treated cells were used as the
control group. Chemosensitivity was shown as IC50 values calculated from full dose–response curves.

Median-effect analysis for treatment synergy. To determine the efficacy of combination of cisplatin
with the anti-ErbB agents, the cells were treated with 0 to 10 μg/mL of cisplatin and different concentrations of
the ErbB inhibitors for 48 h. Survival fractions in each treatment were determined by MTT assay and combination index (CI) was computed using the method developed by Chou and Talalay78 and the computer software
CalcuSyn (Biosoft, Cambridge, UK). CI < 1, CI = 1 and CI > 1 represent synergism, additive effects and antagonism of the two drugs, respectively.
Crystal violet staining.

The cells were plated at a density of 6 × 104 cells in 6-well plates and treated with
the drugs for 48 h. The cultures were then washed with PBS, fixed with ice-cold methanol and stained with crystal
violet (0.5% w/v). The images were acquired with an inverted microscope.
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Colony formation assay.

Single-cell suspensions were seeded in 6-well plates at a density of 500 cells/well.
Once adhered, the cells were treated with the desired concentrations of the drugs for 48 h. The plates were further
incubated for 10 d and colonies were stained with 0.5% crystal violet and counted under an inverted microscope.
Plating efficiency (PE) and survival fraction (SF) were calculated using the following formula: PE = number of
colonies/number of cells seeded; SF = number of colonies/number of cells seeded × PE and plotted graphically
to obtain survival curves.

Anoikis resistance assay.

For anoikis evaluation, 96-well plates were coated with poly-HEMA (20 mg/mL
in 95% ethanol) and dried in a tissue culture hood. The cells were trypsinised into a single cell suspension and
seeded in poly-HEMA-coated plates at a density of 5 × 103 cells/well. The cell suspension cultures were treated
with the desired concentrations of the drugs for 48 h. Cell viability was estimated by MTT assay.

Analysis of gene expression by quantitative reverse transcription-PCR.

The quantitative reverse
transcription-PCR (qRT-PCR) analysis was performed on a LightCycler 96 instrument (Roche Molecular
Diagnostics) using RealQ-PCR Master Mix kit (Ampliqon, Copenhagen, Denmark). The primers used are listed
in Supplementary Table 3. The target gene expression levels were normalised to beta-2-microglobulin (B2M)
levels in the same reaction. For calculations, 2−ΔΔCT formula was used, with ΔΔCT = (CT target − CT B2M)
experimental sample – (CT target − CT B2M) control samples, where CT is cycle threshold79.

Western blot analysis. The cells were lysed with RIPA lysis buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl,
1.0% NP-40, 0.5% sodium deoxycholate and 0.1% SDS) containing protease and phosphatase inhibitors (Roche
Molecular Biochemicals). Protein concentration was determined using the Bradford assay. A total of 50 to 100 μg
of protein were separated by SDS-PAGE and transferred onto PVDF membranes (Membrane Solutions, TX,
USA). Membranes were blocked and blotted with the relevant antibodies. Horseradish peroxidase-conjugated secondary antibodies were detected with a BM chemiluminescence detection kit (Roche Molecular Biochemicals).
β-actin was used as the loading control. All antibody dilutions were 1:500 except for the β-actin antibody, which
was used at a dilution of 1:5000.
Annexin V/PI staining.

Cells were stained with PI and FITC-conjugated Annexin V, as provided by
Annexin-V-FLUOS Staining Kit (Roche Diagnostics) according to the manufacturer’s instructions. The results
were analysed using a Partec PAS III flow cytometer (Partec GmbH) and WindowsTM FloMax software (Partec).

Cell migration and invasion. Transwell cell migration and invasion assays were carried out as described earlier80.
Statistical analysis. All data were evaluated in triplicate against vehicle-treated control cells and collected from
three independent experiments. Data were graphed and analysed by GraphPad Prism Software 7.0a using one-way
ANOVA and the unpaired two-tailed Student’s t-test. All data are presented as mean ± standard deviation (SD).
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